Navigation Links
Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
Date:4/18/2008

00 mg/2,500 mg, and one dose-limiting incident of diarrhea at 2,000 mg/2,500 mg) were transient and medically manageable. The most frequently reported treatment-related grade 2/3 adverse events were hand-foot syndrome (29 percent), leukopenia/neutropenia (24 percent) and fatigue (19 percent).

About XELODA (capecitabine)

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda. For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindicated in patients with severe renal impairment. For patients with moderate renal impairment, dose reduction is required.

The most common adverse events (greater than or equal to 20%) of Xeloda monotherapy were diarrhea, nausea, stomatitis and hand-foot syndrome. As with any cancer therapy, there is a risk of side effects, and these are usually manageable and reversible with dose modi
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015  MEI Pharma, Inc. (Nasdaq: MEIP ), an ... for cancer, announced today that Daniel P. Gold , ... inaugural Cantor Fitzgerald Healthcare Conference on Wednesday, July 8, 2015 ... in New York . A live ... . A replay will be available approximately one hour after ...
(Date:7/1/2015)... 2015 Lupin , ... Total Number of MPP Sub-licensees to Fourteen Companies   ... announced the rapid expansion of its network of generic manufacturers ... to develop MPP-licensed antiretrovirals (ARVs). New companies Lupin and Strides ... new HIV medicine the MPP licensed from ViiV Healthcare two ...
(Date:7/1/2015)... SAN DIEGO , July 1, 2015  AVACEN, Inc. ... a second AVACEN patent covering the medical technology platform supporting ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... The apparatus and methods patent no. 9,066,781 - Methods And ... devices manufactured by AVACEN and specific methods of use, referred ...
Breaking Medicine Technology:MEI Pharma to Present at Cantor Fitzgerald Healthcare Conference 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3AVACEN Medical Patent Issued 2
(Date:7/1/2015)... , ... July 01, 2015 , ... Convoy of ... community celebration in the Twin Cities on Saturday, August 1, at Spring Lake Park ... community will provide more than $1 million worth of goods and services including free ...
(Date:7/1/2015)... Louisville, KY (PRWEB) , ... July 01, 2015 ... ... Health Care Transformation Task Force, contributing to newly released white paper: “Pro-actively Identifying ... The paper was published July 1st and is available at: http://www.hcttf.org/resouces-tools . ...
(Date:7/1/2015)... Columbus, OH (PRWEB) , ... July 01, 2015 , ... ... pleased to announce Dr. Leslie King has been named Dean of the ... role as Dean, Dr. King will promote and support the vision and mission of ...
(Date:7/1/2015)... Luis Obispo, CA (PRWEB) , ... July 01, ... ... non-surgical bunion treatment, announces their big summer sale. Customers purchasing two or ... with promo code "Summer15". , Bunion Bootie temporarily corrects misaligned toes ...
(Date:7/1/2015)... ... ... B. E. Smith, the only full-service leadership solutions firm dedicated exclusively to ... for Capital Health in Pennington, N.J. One of the top ... more than 1,000 healthcare executives into organizations. , Capital Health is a two-hospital ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... A team of French surgeons took off on a specially ... attempt the first-ever operation // carried out in weightless ... ,The Airbus A300 is equipped with a special surgical module, ... future surgery carried out in the gravity-free conditions of outer ...
... of patented drugs will play host to a new entrant ... recent communique // by the Director of patent policy in ... arm for the multitude of generic drug manufacturers, who can ... to developing nations. ,Biolyse Pharma Corp., ...
... in the U.S. uncovered the secrets of the deadly Spanish flu ... across the world.// ,The pandemic took lives of ... severity of the virus was not understood then. ,Dr John Kash, ... a research by infecting mice with a reconstructed form of the ...
... Thiruvananthapuram: The Health Department has announced that it ... both prevention as well as // control measures, ... districts in Kerala, Thiruvananthapuram, Alappuzha, Ernakulum and Kozhikode ... of a slackened response by the Health watch ...
... a division that deals with the reconstruction of the ... the occurrence of birth defects like cleft palate. Since ... required. This will not only ensure a smooth operation, ... their face will look like in future., ,In ...
... cornea cells that may also explain how it evades the ... University of Illinois at Chicago College of Medicine. ... Journal of Cell Biology. ,Both strains of the ... on the mouth, and HSV-2, genital herpes -- can infect ...
Cached Medicine News:Health News:Spanish flu virus – secrets uncovere 2Health News:Mathematics And Beauty? You Bet! 2Health News:Herpes Infects Cornea, Evades Immune Cells 2
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... handheld oximeter has been converted to the ... now compatible with the entire line of ... Sensor and SoftCare Nonadhesive Sensors. The redesigned ... Nellcor's latest advanced signal processing technology, which ...
... expanding the growing portfolio of OxiMax® ... is a compact, affordable bedside monitor. ... processing technology, it offers reliable operation ... compatible with the complete family of ...
The Model 900 is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring. It also incorporates an LCD waveform m...
Medicine Products: